Document:

Exhibit
10.2

 

 

OPTION
AGREEMENT No. 32

PURCHASE
COMMON STOCK OF

NOVO
INTEGRATED SCIENCES, INC.

 

On
this 6th day of August, 2020, NOVO INTEGRATED SCIENCES, INC., a Nevada corporation (the “Company”) hereby grants,
as of the date hereof, to Christopher David, an individual (hereinafter “Optionee”), upon the terms and conditions
hereinafter set forth, FIVE MILLION SEVEN HUNDRED FIFTY THOUSAND (5,750,000) options to purchase shares of the Company’s
common stock (the “Option”) at an exercise price of THIRTY CENTS ($0.30). The Expiration Date of the Options is defined
hereinafter in Section 1 (b).

 

These
Options are granted to Optionee in accordance with the terms and conditions of the Employment Agreement, dated August 6, 2020
(the “Agreement”), between Mr. David and the Company which provides for Mr. David to remain fulfilling the roles and
responsibilities as the Company’s President.

 

1.
Exercise of Options.

 

(a)
Subject to subsection (b) of this Section 1, these options may be exercised, in whole or in part, upon presentation, to the Company
at Novo Integrated Sciences, Inc. Attention: CEO/President, 11120 NE 2nd Street, Suite 200, Bellevue, Washington,
98004 or at such other address as the Company may designate as the Company’s principal corporate address; of (i) the
attached Exercise Form (Exhibit A) duly executed and delivered notice to Optionee; together with (ii) either (x) a wire transfer,
certified bank or cashier’s check payable to the order of Company in the amount of the Exercise Price or (y) the Optionee’s
election to Net Exercise in accordance with the following formula:

 

Net
Exercise Formula (Cashless): The Holder may elect to receive Option Shares equal to the value of this Option (or the portion
thereof being canceled) pursuant to a Net Exercise Formula whereby the Company shall issue to the Holder a number of Option Shares
computed using the following formula:

 

	 	              Y
        (A-B)

        X
        = ———————

                           A

 

	Where:	X	=	the
    number of the Option Shares to be issued to the Holder.
	 	 	 	 
	 	Y	=	the
    number of the Option Shares purchasable under this Warrant.
	 	 	 	 
	 	A	=	the
    fair market value of one Share on the date of determination.
	 	 	 	 
	 	B	=	the
    per share Exercise Price (as adjusted to the date of such calculation).

 

Fair
Market Value. For purposes of this Section, the per share fair market value of the Option Shares shall mean the average of
the closing prices of the Common Stock as quoted on the Over-the-Counter Bulletin Board, or the principal exchange on which the
Common Stock is listed, in each case for the ten (10) trading days ending three (3) trading days prior to the date of determination
of fair market value.

 

11120
NE 2nd Street, Suite 200 Bellevue, WA 98004 USA

Phone:
(206) 617-9797

www.novointegrated.com

 

    	 	 	 

    	 	 	Page | 2

    

 

(b)
Expiration Date. These Options to purchase 5,750,000 shares of the Company’s common stock must be exercised, in whole
or in part, on or before August 6, 2025, which is five (5) years from the grant date (the “Expiration Date”).

 

(c)
Exercise Price. The Options shall be exercisable at thirty cents ($0.30) per option (i.e. the “Exercise Price”).

 

2.
Vesting. All 5,750,000 options fully-vest as of the date hereof, August 6, 2020.

 

3.
Purchased and Underlying Common Stock. 

 

(a)
Upon receipt of an Exercise Form and payment of the Exercise Price (or Net Exercise election), the Company shall issue and cause
to be delivered with all reasonable dispatch to Optionee, a certificate or certificates for the number of full shares of Common
Stock comprising the applicable Common Stock so purchased upon the exercise of a vested Option (the “Purchased Common Stock”).
Such certificate or certificates shall be deemed to have been issued, and any person named therein shall be deemed to have become
a holder of record of such Common Stock, as of the date of receipt of the Exercise Form and payment of the Exercise Price (if
required), notwithstanding that the certificates representing such Common Stock shall not actually have been delivered or that
the transfer shall not have been reflected on the stock transfer books of Company.

 

(b)
the Company shall at all times keep reserved so long as this Option remains outstanding, out of its authorized common stock, sufficient
common stock as shall continue to be subject to purchase under this Option (the “Underlying Common Stock”).

 

4.
Rights and Obligations of Optionee.

 

(a)
Optionee or any subsequent holder of this Option shall not, by virtue hereof, be entitled to any rights of a shareholder in Company,
either at law or in equity.

 

(b)
Optionee or any subsequent holder of this Option, as such, shall not be entitled to vote or receive dividends or to be deemed
the holder of the Common Stock for any purpose, nor shall anything contained in this Option Agreement, confer upon Optionee any
of the rights of a shareholder of Company including, but not limited to, any right to vote, give or withhold consent to any action
by Company, whether upon any reclassification of stock, consolidation, merger, share exchange, conveyance or otherwise, receive
notice of meetings or other action affecting shareholders (except for the notices provided for herein), receive dividends, receive
subscription rights, or any other right until this Option shall have been exercised and Optionee shall have become the record
holder of the Common Stock, as provided herein.

 

(c)
In the event that the number of authorized shares is altered, pursuant to stock splits, initial public offerings, or other activity,
all of the shares granted to the Executive hereunder shall be adjusted proportionately.

 

5.
Purchased Common Stock. The Company covenants and agrees that all Purchased Common Stock to be delivered upon proper exercise
of this Option shall be recorded on the books of Company in the name of Optionee and shall be duly and validly authorized and
issued, fully paid and non-assessable, and free from all preemptive rights, taxes (other than transfer taxes), liens, charges
and security interests created by Company with respect to the issuance thereof.

 

    	 	 	 

    	 	 	Page | 3

    

 

6.
Disposition of Options or Common Stock.

 

(a)
Optionee and/or any transferee hereof or of the Purchased Common Stock by its acceptance hereof or thereof, hereby understands
and agrees that neither this Option nor the Purchased Common Stock have been registered under U.S. Securities Act of 1933, as
amended (the “Securities Act”) or applicable state securities laws (the “State Acts”) and shall not be
sold, pledged, hypothecated, donated or otherwise transferred (whether or not for consideration) except upon the issuance to Company
of a favorable opinion of counsel or submission to Company of such evidence as may be reasonably satisfactory to counsel to Company,
in each such case, to the effect that any such transfer shall not be in violation of the Securities Act and/or the State Acts.
It shall be a condition to the transfer of this Option that any transferee hereof deliver to Company its written agreement to
accept and be bound by all of the representations, terms and conditions of this Option.

 

(b)
The stock certificates of Company that will evidence the Purchased Common Stock may be imprinted with a restrictive legend in
substantially the following form:

 

THE
SECURITIES EVIDENCED BY THIS OPTION HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS
OF ANY STATE AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO ANY EFFECTIVE REGISTRATION
STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR PURSUANT TO AN EXEMPTION FROM REGISTRATION THEREUNDER AND UNDER APPLICABLE
STATE LAW, THE AVAILABILITY OF WHICH MUST BE ESTABLISHED TO THE SATISFACTION OF THE COMPANY.

 

Company
has not agreed to register any of the Purchased Common Stock for distribution in accordance with the provisions of the Securities
Act or the State Acts. Except as otherwise set forth herein, Company has not agreed to comply with any exemption from registration
under the Securities Act or the State Acts for the resale of such Common Stock. Hence, it is the understanding of Optionee that
by virtue of the provisions of certain rules respecting “restricted securities” promulgated by the U.S. Securities
and Exchange Commission, all or part of the Purchased Common Stock may be required to be held indefinitely, unless and until registered
under the Securities Act and the State Acts, or unless an exemption from such registration is available (in which case Optionee
may still be limited as to the amount of such Common Stock that may be sold).

 

7.
Representations.

 

(a)
Risk Factors. Optionee understands and acknowledges that (i) this Option and the Purchased Common Stock are unregistered,
restricted securities and are not readily marketable and (ii) there is a significant degree of risk in investing in the Common
Stock. Optionee agrees that he must be able to bear the economic risk of the loss of the entire investment in the Common Stock
if it exercises this Option.

 

(b)
Knowledge and Experience; Financial Capability and Net Worth. Optionee has (i) such knowledge and experience in financial
and business matters that it is capable of evaluating the merits and risk of the investment in the Common Stock, (ii) has determined
that such investment is suitable for Optionee in view of its financial circumstances and available investment opportunities; and
(iii) no need for liquidity of the investment and no reason to anticipate any change in Optionee’s financial circumstances
which may cause or require any sale, transfer or other distribution of the Purchased Common Stock.

 

(c)
Information. Optionee agrees that it shall be its responsibility to request such information with respect to Company as
it and its advisors deem appropriate to evaluate the risks and merits of investment in the Purchased Common Stock at the time
that Optionee exercises this Option.

 

8.
Remedies. The Company stipulates that the remedies at law of Optionee in the event of any default or threatened default by
Company in the performance of or compliance with any of the terms of this Option are not and will not be adequate and that, without
limiting any other remedy available at law, such terms may be specifically enforced by a decree for the specific performance of
any agreement contained herein or by an injunction against a violation of any of the terms hereof. The rights and remedies of
Optionee are cumulative and not exclusive of any rights or remedies which Optionee might otherwise have.

 

    	 	 	 

    	 	 	Page | 4

    

 

9.
Survival. The various rights and obligations of Optionee hereof as set forth herein shall survive the exercise of this Option
at any time or from time to time and the surrender of this Option.

 

10.
Change; Waiver. Neither this Option nor any term hereof may be changed, waived, discharged or terminated orally, but only
by an instrument in writing signed by the party against which enforcement of the change, waiver, discharge or termination is sought.
No failure or delay of Optionee in exercising any power or right hereunder shall operate as a waiver thereof, nor shall any single
or partial exercise of any such right or power, or any abandonment or discontinuance of steps to enforce such a right or power,
preclude any other or further exercise thereof or the exercise of any other right or power.

 

11.
Governing law. The execution, effectiveness, construction, performance, amendment and termination of this Option and the resolution
of disputes hereunder shall be governed under the laws of Nevada.

 

12.
Confidentiality. The parties acknowledge that the existence and the terms of this Option and any oral or written information
exchanged between the parties in connection with the preparation and performance this Option are regarded as confidential information.
Each party shall maintain confidentiality of all such confidential information, and without obtaining the written consent of the
other party, it shall not disclose any relevant confidential information to any third parties, except for the information that:
(a) is or will be in the public domain (other than through the receiving party’s unauthorized disclosure); (b) is under
the obligation to be disclosed pursuant to the applicable laws or regulations, rules of any stock exchange, or orders of the court
or other government authorities; or (c) is required to be disclosed by any party to its shareholders, investors, legal counsels
or financial advisors regarding the transaction contemplated hereunder, provided that such shareholders, investors, legal counsels
or financial advisors shall be bound by the confidentiality obligations similar to those set forth in this Section. This Section
shall survive the termination of this Option for any reason.

 

13.
Severability. In the event that one or several of the provisions of this Option are found to be invalid, illegal or unenforceable
in any aspect in accordance with any laws or regulations, the validity, legality or enforceability of the remaining provisions
of this Option shall not be affected or compromised in any respect. The parties shall strive in good faith to replace such invalid,
illegal or unenforceable provisions with effective provisions that accomplish to the greatest extent permitted by law and the
intentions of the parties, and the economic effect of such effective provisions shall be as close as possible to the economic
effect of those invalid, illegal or unenforceable provisions.

 

14.
Successors. This Option shall be binding on and shall inure to the interest of the respective successors of the parties and
the permitted assigns of such parties.

 

15.
Counterparts. This Option may be executed in any number of counterparts and by facsimile transmission, each of which shall
be deemed to be an original instrument, but all of which taken together shall constitute one and the same agreement. Facsimile
signatures shall be deemed to be original signatures for all purposes.

 

[Remainder
of Page Intentionally Left Blank]

 

    	 	 	 

    	 	 	Page | 5

    

 

IN
WITNESS WHEREOF, the parties hereto have executed this Option as of the date first above written.

 

	By:
    Novo Integrated Sciences, Inc.	 	 
	 	 	 
	/s/
    Robert Mattacchione	 	Date:
    August 6, 2020
	Robert
    Mattacchione	 	 
	CEO
    and Board Chairman	 	 
	 	 	 
	/s/
    Mike Gaynor	 	Date:
    August 6, 2020
	Michael
    Gaynor	 	 
	Secretary
    and Director	 	 

 

[Remainder
of Page Intentionally Left Blank]

 

    	 	 	 

    	 	 	Page | 6

    

 

CERTIFICATE

OF

OPTIONS

 

	Certificate
    Number: #32	Options:
    5,750,000

 

This
Certifies that Christopher David, an individual, is the owner of FIVE MILLION SEVEN HUNDRED FIFTY THOUSAND (5,750,000) options
of Novo Integrated Sciences, Inc. common shares fully paid and non-assessable, transferable only on the books of the Corporation
in person, or by designated attorney, upon surrender of this Certificate properly endorsed.

 

This
Certificate is granted in accordance with the terms of Option Agreement No. 32, dated August 6, 2020, to purchase common stock
of Novo Integrated Sciences, Inc., a Nevada corporation. The options, provided for in this Option Agreement No. 32:

 

	 	●	grant
    on August 6, 2020
	 	●	fully-vest
    on August 6, 2020
	 	●	have
    an exercise price of thirty cents ($0.30) per option.
	 	●	expire
    on August 6, 2025 (5-years years from the grant date).
	 	●	are
    exercisable, in whole or in part, at any-time from the vest date until the expiration date.

 

In
Witness Whereof, the said Corporation has caused this certificate to be signed by its duly authorized officers and its Corporate
Seal to be hereunto affixed this 6th Day of August, A.D. 2020.

 

	/s/
    Robert Mattacchione	 	/s/
    Michael Gaynor
	Robert
    Mattacchione	 	Michael
    Gaynor
	CEO
    and Board Chairman	 	Secretary
    and Director

 

[Corporate
Seal]

 

    	 	 	 

    	 	 	Page | 7

    

 

EXERCISE
FORM

TO:
NOVO INTEGRATED SCIENCES, INC. 

Attention:
CEO-President

11120
NE 2nd Street, Suite 200

Bellevue,
Washington 98004

 

The
undersigned, being the lawful holder of the Option evidenced by the attached Option Agreement, elects to purchase __________________________________________________
shares the Common Stock of NOVO INTEGRATED SCIENCES, INC., at an Exercise Price of Thirty cents ($0.30) per option and
elects either:

 

	 	(a)	[  ]
    Cash Exercise: the Holder hereby makes payment of U.S $____________ in payment of the purchase price thereof, which
    includes the Exercise Price in full, together with all applicable transfer taxes, if any; or
	 	(b)	[  ]
    Net Issue Exercise (Cashless): The Holder elects to receive Option Shares equal to the value of this Option (or the
    portion thereof being canceled) whereby the Company shall issue to the Holder a number of Option Shares computed using the
    following formula:

 

	 	               Y
        (A-B)

        X
        = ———————

                          A

 

	Where:	X	=	the
    number of the Option Shares to be issued to the Holder.
	 	 	 	 
	 	Y	=	the
    number of the Option Shares purchasable under this Warrant.
	 	 	 	 
	 	A	=	the
    fair market value of one Share on the date of determination.
	 	 	 	 
	 	B	=	the
    per share Exercise Price (as adjusted to the date of such calculation).

 

Fair
Market Value. For purposes of this Section, the per share fair market value of the Option Shares shall mean the average of
the closing prices of the Common Stock as quoted on the Over-the-Counter Bulletin Board, or the principal exchange on which the
Common Stock is listed, in each case for the ten (10) trading days ending three (3) trading days prior to the date of determination
of fair market value.

 

Signature:
_______________________________________

 

Print
Name: ______________________________________Date: ______________________

 

Social
Security Number: _______________________________________

 

Address:
_______________________________________

_______________________________________

________________________________________

 

Phone
No. _________________________________Email: _________________________________Exhibit 10.20

 

SECOND AMENDMENT

TO

EMPLOYMENT
AGREEMENT

 

This
Second Amendment to Employment Agreement (the “Second Amendment”) is made and effective as of July 1, 2020, between
Modular Medical, Inc., a Nevada corporation (the “Company”), and Paul M. DiPerna (“Executive”) (each a “Party”
and collectively the “Parties”).

 

WHEREAS,
the Parties entered into an Employment Agreement effective as of August 1, 2018, as amended by that first amendment dated May
12, 2020, setting forth the terms and conditions of Executive’s employment as Company’s President and Chief Executive
Officer (the “Employment Agreement”); and

 

WHEREAS,
the Parties to desire to further amend the Employment Agreement as set forth in this Second Amendment.

NOW,
THEREFORE, in consideration of the premises and mutual covenants herein contained, the receipt and sufficiency of which the Parties
hereby acknowledge, the Parties agree as follows:

		1.	The
                                         Employment Agreement is hereby amended as follows:

Section
3., Compensation, is hereby amended by deleting existing subsection (a) Base Compensation and inserting the following new subsection
(a):

(a)   Base
Compensation. Executive shall be paid a cash salary of $300,000 annually (the “Base Compensation”) as follows:
Executive shall receive a cash salary of $200,000 per year (the “Cash Salary”) and a deferred salary of $100,000 per
year (the “Deferred Salary”). Payment of the Deferred Salary shall initially be deferred and accrue for Executive’s
benefit until the Company has received $5,000,000 of cumulative gross proceeds from its financing activities initiated in calendar
year 2020. The cumulative amount of the Deferred Salary shall be paid to Executive in the first payroll after achievement of $5,000,000
of financing gross proceeds. After the cumulative Deferred Salary has been paid to Executive, the salary deferrals will cease
and the Base Compensation shall be paid entirely in cash. The Base Compensation shall be payable less applicable deductions and
withholding in normal installments and in accordance with the payroll practices of Company. Executive’s Base Compensation
shall not be reduced without agreement of Executive.

		2.	Except as modified by this
Second Amendment, the terms and conditions of the Employment Agreement remain in full force and effect.

		3.	This Second Amendment may
be executed in one or more counterparts, each of which shall be deemed an original, but all of which shall constitute one and
the same instrument.

		4.	This Second Amendment has
been approved by action of the Company’s Board of Directors on June 26, 2020.

    	 

    	 

    

IN WITNESS WHEREOF, the parties have duly
executed this Second Amendment as of the date first above written.

 

	EXECUTIVE	 	COMPANY
	 	 	 	 
	/s/ Paul M. DiPerna	 	By: 	/s/ William J Febbo
	Paul M. DiPerna	 	 	William J. Febbo
	 	 	 	Chairman of the Compensation
	 	 	 	Committee of the Board of Directors

    	2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00312-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00312-of-00352.parquet"}]]